Format

Send to

Choose Destination
Expert Opin Biol Ther. 2008 Sep;8(9):1407-15. doi: 10.1517/14712598.8.9.1407 .

The evolving role of catumaxomab in gastric cancer.

Author information

1
University of Heidelberg, National Center for Tumour Diseases, Department of Medical Oncology, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany. florian.lordick@med.uni-heidelberg.de

Abstract

BACKGROUND:

Gastric cancer is a condition with a high medical need. Even after R0 resection the rate of peritoneal and other distant site recurrences is high. Novel therapeutic approaches include trifunctional antibodies (trAb) that recruit and activate different types of immune effector cells at the tumour site. The trAb catumaxomab has dual antigen specificity for epithelial cell adhesion molecule and CD3 and binds to Fcgamma-receptor-positive accessory cells. Intraperitoneal administration of catumaxomab in patients with malignant ascites due to epithelial cancer significantly increased puncture-free survival.

OBJECTIVE:

To review the mode of action of catumaxomab and describe clinical data regarding the emerging role of catumaxomab in the treatment of patients with gastric cancer. A summary of completed and ongoing clinical trials including patients with gastric cancer is given.

CONCLUSION:

Catumaxomab is a promising approach in the treatment of patients with gastric cancer.

PMID:
18694358
DOI:
10.1517/14712598.8.9.1407
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center